March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
1 citations
,
August 2024 in “British Journal of Dermatology” Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
Adalimumab significantly improved Hidradenitis Suppurativa and quality of life in two patients.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The model improves understanding of androgen interactions by focusing on signal intensity and system capacity.
9 citations
,
January 2015 in “Dermatology Online Journal” A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.
January 2026 in “Pattern Recognition” The new method improves accuracy in segmenting scalp tissue layers.
Farudodstat may effectively treat alopecia areata by protecting hair follicles without harmful effects.
June 2025 in “British Journal of Dermatology” ALUDWIG can help standardize female hair loss assessment from a single image.
December 2024 in “Frontiers in Pharmacology” Araliadiol may promote hair growth like minoxidil without being toxic.
66 citations
,
April 1989 in “Alcoholism Clinical and Experimental Research” The ethanol patch test reliably identifies ALDH phenotype.
47 citations
,
October 2021 in “Journal of Nanobiotechnology” HPDAlR nanoparticles greatly improve skin wound healing without toxicity.
December 2023 in “Journal of health and rehabilitation research” Oral Apremilast effectively treats alopecia areata in most patients.
September 2023 in “Nature communications” Alk1 in specific cells is crucial for proper nerve branching and hair function.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
May 2023 in “Advances in medicine” Alopecia areata significantly impacts patients' mental health and quality of life.
January 2018 in “Elsevier eBooks”
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
October 2022 in “Zenodo (CERN European Organization for Nuclear Research)”
1 citations
,
January 2023 Alopecia Areata significantly reduces quality of life, especially in women, long-term sufferers, and severe cases.
November 2024 in “Skin Appendage Disorders” Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
February 2025 in “Pediatric Dermatology” 24 citations
,
March 2022 in “Journal of the American Academy of Dermatology” Adalimumab improved folliculitis decalvans in most patients.
5 citations
,
December 2024 in “Patient Preference and Adherence” Patients with alopecia areata in Saudi Arabia understand the condition's seriousness but still face significant psychological challenges.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
October 2025 in “Editora Pasteur eBooks” 5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
19 citations
,
January 2016 in “Annals of Dermatology” Dutasteride is safe and effective for treating hair loss, but may decrease libido.